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PRole of Reticulated Platelets and Platelet
Size Heterogeneity on Platelet Activity After Dual
Antiplatelet Therapy With Aspirin and Clopidogrel
in Patients With Stable Coronary Artery Disease
Sasidhar Guthikonda, MD, MPH, FACC,* Carlos L. Alviar, MD,* Muthiah Vaduganathan, BS,*
Mehmet Arikan, MD,* Armando Tellez, MD,* Timothy DeLao, MLT,* Juan F. Granada, MD,*
Jing-Fei Dong, MD, PHD,† Neal S. Kleiman, MD, FACC,* Eli I. Lev, MD*
Houston, Texas
Objectives The aim of this study was to evaluate the relationship between reticulated platelets (RPs), platelet size, and
platelet function in patients with stable coronary artery disease (CAD) taking aspirin and clopidogrel.
Background Reticulated platelets are young platelets that are larger and possibly more active than non-RPs.
Methods Flow cytometry was used to measure RPs after staining with thiazole orange and to define the upper 20% and lower
20% of platelets by size. Platelet aggregation was measured with light transmission aggregometry (LTA); platelet acti-
vation was assessed by measuring activated platelet surface expression of P-selectin and glycoprotein (GP) IIb/IIIa.
Results Ninety patients were recruited and stratified into tertiles of %RPs. Patients in the upper tertile displayed greater plate-
let aggregation to 5-mol/l adenosine diphosphate (ADP) (50.7 16.4% vs. 34.2  17.3%, p  0.001), 1.5-mmol/l
arachidonic acid (AA) (27.3 16.9% vs. 11.7  9.3%, p  0.001), and 1-g/ml collagen (18  11.6% vs. 12.1 
8.7%, p  0.05) and greater expression of GP IIb/IIIa (4.7 1.8% vs. 3.1  2.2%, p  0.001). Frequency of low re-
sponse to aspirin (AA LTA 20%) was higher in the upper tertile (53% vs. 17%, p 0.001) compared with the lower
tertile; low response to clopidogrel (ADP LTA50%) was also elevated in the upper tertile (50% vs. 13%, p 0.003).
The larger platelet gate had a higher % of RPs compared with the smaller gate (15.4 16.7% vs. 1.7  2.3%, p 
0.001) and greater GP IIb/IIIa (5.7 3.1 vs. 2.1  1.2, p  0.001) and P-selectin expression (7.8 4.9 vs. 4.6 
2.7, p  0.001).
Conclusions The proportion of circulating RPs strongly correlates with response to antiplatelet therapy in patients with stable
CAD. Large platelets exhibit increased reactivity despite dual antiplatelet therapy, compared with smaller
platelets. (J Am Coll Cardiol 2008;52:743–9) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.05.031t
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(ntiplatelet therapies with aspirin and clopidogrel have
een widely used to prevent thromboembolic events in
elected patients with coronary atherosclerosis (1–5). It is
enerally accepted that the principal mechanism of this
ffect occurs through inhibition of platelet activation and
ggregation. Several studies have suggested wide inter-
ndividual variability in the responses to aspirin and clopi-
ogrel, as assessed with ex vivo platelet function assays
6–8). A low degree of inhibition in the platelets of patients
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ccepted May 12, 2008.reated with these drugs has been termed “resistance” to
spirin or clopidogrel and has been implicated in adverse
ardiovascular outcomes, particularly after percutaneous
oronary intervention (9,10). The mechanisms for this
henomenon are unclear, and methods to identify and treat
t are still being elucidated.
One possible mechanism is an elevated turnover of the
irculating platelet pool, yielding a larger population of
oung platelets that are more reactive than an older popu-
ation of platelets. Circulating reticulated platelets (RPs) are
dentifiable on the basis of staining for messenger ribonu-
leic acid. This population is generally believed to represent
ounger platelets, with increased mean volume and a greater
umber of dense granules than older circulating platelets
11). The RPs are elevated in patients with acute coronary
yndromes and stroke (12,13), although it is not clear
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cause of clinical instability or is a
consequence of the syndrome.
We recently reported in a popu-
lation of healthy subjects that an
elevated platelet turnover, as re-
ported by the RP fraction, is
associated with increased platelet
aggregation and activity and de-
creased responses after a single
dose of aspirin (14). It is not
known whether platelet re-
sponses to chronic aspirin and
clopidogrel therapy in patients
with coronary artery disease
(CAD) are dependent on the
proportion of circulating RPs.
Younger platelets tend to be
arger in size, and thus large platelets could be a reflection of
he number of RPs, although not all large platelets are
oung platelets. It is also believed that platelet size is
etermined at the time of megakaryocyte production and
elease of platelets (15). Platelets with increased platelet
olume are more reactive hemostatically, aggregate more
apidly in response to collagen (16), synthesize more throm-
oxane B2 (17,18), release more serotonin granules, and
xpress more glycoprotein (GP) Ib and GP IIb/IIIa (19). It
s thus possible that large platelets might respond differently
o antiplatelet therapy compared with smaller platelets.
arge platelets could also potentially affect responses to
ntiplatelet therapy independent of %RPs, by expressing
arger amounts of cyclooxygenase (COX)-1, adenosine
iphosphate (ADP) receptors, and alpha-granule proteins,
hus making them more reactive. Mean platelet volume
MPV) is a measure of platelet size, is elevated in unstable
ngina and acute myocardial infarction (MI) (20,21), and is
ssociated with worse cardiovascular outcomes after MI (22)
r stroke (23). Whether platelet size, in addition to the
resence of younger platelets, plays a role in modifying
esponses to antiplatelet therapy is not known.
We hypothesized that increased proportions of RPs and
latelet size are associated with increased platelet reactivity
espite dual antiplatelet therapy in patients with stable
AD taking both aspirin and clopidogrel. We sought to
rimarily use flow cytometry platelet size data along with
PV values to evaluate platelet size responses.
ethods
tudy population. The study was approved by the Insti-
utional Review Board of the Methodist Research Institute;
ll subjects provided informed consent. We enrolled pa-
ients with known stable CAD who were admitted to the
ethodist DeBakey Heart Center from October 2005 to
uly 2007, were scheduled to undergo elective cardiac
Abbreviations
and Acronyms
AA  arachidonic acid
ADP  adenosine
diphosphate
CAD  coronary artery
disease
CHF  congestive heart
failure
COX  cyclooxygenase
GP  glycoprotein
LTA  light transmission
aggregometry
MPV  mean platelet
volume
RP  reticulated plateletatheterization and/or planned percutaneous coronary inter- aention, and who were taking both clopidogrel (75 mg
aily) and aspirin (81 to 325 mg daily) for at least 1 week;
o additional loading dose of clopidogrel was administered.
hese subjects were not recruited consecutively but ran-
omly, and all patients we approached agreed to participate
n the study. Exclusion criteria were administration of any
P IIb/IIIa antagonist during the week before the study,
cute MI in the week before the study, hemodynamic
nstability, recent history of cardiac arrest or cardiopulmo-
ary resuscitation, thrombocytopenia (100  103 cells/
m3), anemia (hemoglobin 10 g/dl), or renal failure
creatinine 2.5 mg/dl). Blood samples were collected in
he morning before administration of that day’s antiplatelet
herapy, with the last antiplatelet therapy administered at
east 12 h prior, so that the acute effects of aspirin intake did
ot confound the results and adequate time was given for
ew platelet release. Samples were collected from an ante-
ubital vein through a 21-gauge needle the morning before
he performance of the catheterization. Blood was collected
n tubes containing 3.2% citrate. The tubes were filled to
apacity and then gently mixed. Blood samples were pro-
essed within 2 h of blood collection without stasis (by
lacing in a machine that gently rolls the tubes
ontinuously).
ight transmission aggregometry. Turbidimetric platelet
ggregation was performed in platelet-rich plasma with a
latelet count adjusted to 250  103/mm3. Platelets were
timulated with 5-mol/l ADP, 1.5-mmol/l arachidonic
cid (AA), and 1 g/ml collagen. Aggregation was per-
ormed with a BioData PAP-8 platelet aggregometer (Bio-
ata Corp., Horsham, Pennsylvania). The extent of aggre-
ation was defined as the maximal amount of light
ransmission reached 6 min after addition of the agonist,
ith platelet-poor plasma used as a reference. “Low re-
ponse” to aspirin was defined as platelet aggregation 20%
n response to 1.5-mmol/l AA. “Low response” to clopi-
ogrel was defined as platelet aggregation50% in response
o 5-mol/l ADP. Both of these definitions have been used
n prior reports, and these thresholds of post-treatment
latelet aggregation were demonstrated to be associated
ith a higher risk of ischemic events (10,24–26). “Low
esponse” to both aspirin and clopidogrel was present when
atients met both criteria.
P IIb/IIIa and P-selectin expression. Platelet activation
as determined by platelet surface expression of P-selectin
nd GP IIb/IIIa with whole blood flow cytometry as
reviously described (27). Briefly, activated GP IIb/IIIa
as assessed with a fluorescein isothiocyanate (FITC)-
onjugated PAC-1 antibody (Becton Dickinson, San Jose,
alifornia), and P-selectin expression was determined with
n R-phycoerythrin (PE)-conjugated anti-CD62P antibody
BD Pharmingen, San Jose, California). Five microliters of
itrated whole blood were diluted with 70 l of Tyrodes/
ovine serum albumin followed by 5 l of 200-mol/l ADP
10 mol/l final concentration) and then by 20 l of
nti-CD62b or PAC-1 antibody directed against integrin
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ith phosphate-buffered saline containing 1% paraformal-
ehyde. Samples were analyzed with a Coulter Epics XL
CL flow cytometer (Beckman-Coulter, Miami, Florida).
nstimulated samples served as negative controls. Both
AC-1 binding and P-selectin expression were expressed as
bsolute difference in log mean fluorescence intensity be-
ween unstimulated and stimulated samples.
Ps. Reticulated platelets were measured with a previously
escribed flow cytometry assay (13,27,28), which is an
ppropriate method of measuring young platelets and plate-
et turnover that has been validated in multiple studies
29,30). Five microliters of whole blood were added to a
ube containing 1 ml of 10% thiazole orange (ReticCount,
ecton Dickinson) and a second tube containing 1 ml of
soflo (Beckman-Coulter) as a control. After incubation for
0 min in the dark, the tubes were spun at 1,200 g for 2.5
in to form a cellular pellet. The supernatant was discarded,
nd the pellet was resuspended in 1 ml of Isoflo. Within 1 h,
ow cytometry was performed counting 5,000 stained plate-
ets in the platelet gate. The platelets demonstrating an
ncrease in the mean fluorescence intensity beyond a thresh-
ld margin set at 1% of all platelets at baseline were
ounted as RPs and expressed as a percentage of total
latelets counted.
latelet size. Platelet size was obtained with 2 methods:
) flow cytometry size-gating with forward scatter; and
) MPV values. With flow cytometry, platelet size gates
ere established with forward scatter profiles to determine
emographic and Hematologicalharacterist s of the Patients n the 3 Tertiles of RPs
Table 1 Demographic and HematologicalCharacteristics of the Patients in the 3 Tertiles of RPs
Lower Tertile
(n  30)
Middle Tertile
(n  30)
Upper Tertile
(n  30)
Age (yrs) 67 14 62 10 66 10
Gender (% male) 80 77 63
Race (% Caucasian) 43 53 43
Body mass index (kg/m2) 34 12 30 5 30 5
Systolic BP (mm Hg) 127 26 143 21 138 16
Diastolic BP (mm Hg) 71 17 75 11 75 11
Heart rate (beats/min) 73 9 68 12 74 11
White blood cells (103/mm3) 7.4 2.2 7.1 2.1 7.6 2
Hemoglobin (g/dl) 13.2 1.5 13.3 1.8 12.7 1.8
Platelets (102/mm3) 217 53 199 48 207 60
MPV (fl)* 9.9 0.6 9.9 0.5 10.5 0.9
RPs (%)* 1.3 0.7 3.1 0.8 17.9 8.1
Creatinine (mg/dl) 1.3 0.5 1.1 0.2 1.4 1.2
Diabetes (%) 33 27 40
Hypertension (%) 57 57 63
Hyperlipidemia (%) 43 50 60
Smoking (%) 23 7 17
Stroke (%) 23 7 17
CHF (%)* 20 3.3 3.3
History of MI (%) 30 17 30
p  0.05.
BP  blood pressure; CHF  congestive heart failure; MI myocardial infarction; MPV mean
latelet volume; RP  reticulated platelet.he largest 20% of platelets and the smallest 20% oflatelets, to obtain discretely different platelet size popula-
ions. This method, however, did not provide absolute
latelet sizes. P-selectin expression, PAC-1 antibody bind-
ng, and the number of RPs were measured in platelets
alling within these gates. The MPV values were obtained
ith an automated machine along with the hemogram.
tatistical analysis. Patients were stratified into ascending
ertiles according to the proportion of circulating RPs. An
D of 10% was assumed, and calculations were based on a
ower of 80% and a significance level of 0.05. On the basis
f our prior study (14), we determined that a sample
opulation of more than 60 patients would be sufficient to
emonstrate differences in platelet function with %RPs.
low cytometry platelet size-gating was used to study the
ffects of platelet size on platelet function. When using
PV for platelet size, this sample size would have insuffi-
ient power to study the platelet effects of MPV (because of
he narrow range of MPVs) and hence was not the primary
nd point of this study. Normally distributed data are
xpressed as mean  SD. The Student unpaired t test was
sed to compare means between any 2 groups. One-way
nalysis of variance was used to analyze differences in means
etween tertiles, because data were normally distributed.
he chi-square test was used to compare the upper tertile
ith the other 2 tertiles for dichotomous variables. Multiple
inear and logistic regression analysis was performed to test
he significance of %RPs and MPV on platelet activation
nd response rates. A p value 0.05 was considered to be
tatistically significant.
esults
emographic and hematological characteristics. Clinical
nd hematological parameters were no different between the
ertiles of patients apart from an elevated MPV in the upper
ertile (expected because of stratification on the basis of RPs,
hich are larger). Although the prevalence of congestive
eart failure (CHF) was higher in the lower tertile, the
ctual number of patients with CHF was very low (6 of 30
Figure 1 Aggregation of Reticulated Platelets in Response to
5-M ADP, 1.5-mmol/l AA, and 1-g/ml Collagen
Mean  SEM; p value for t test upper versus lower tertile.
AA  arachidonic acid; ADP  adenosine diphosphate.
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Reticulated Platelets and Antiplatelet Therapy August 26, 2008:743–9n the lower tertile vs. 1 of 30 in the other 2 tertiles) (Table
). Of 90 patients, 55 were taking 325 mg of aspirin daily
nd 35 patients were taking 81 mg of aspirin daily before
nrollment.
latelet aggregation. Light transmission aggregometry
LTA) in response to 5-mol/l ADP, 1.5-mmol/l AA, or
-g/ml collagen was significantly higher in the upper
ertile of RPs compared with both the middle and lower
ertiles (Fig. 1, Table 2).
latelet activation. Activated GP IIb/IIIa expression was
reater in the upper tertile of patients (4.7  1.8) compared
ith the middle and lower tertiles (2.9 1.6 and 3.1 2.2,
espectively, p  0.001). However, expression of P-selectin
as no different between the 3 tertiles (Table 2).
spirin dose and platelet responses. There were no dif-
erences in either platelet activation or aggregation with
ither the 81- or 325-mg dose of aspirin. When analyzed in
Figure 2 Percentage of Patients With Low
Responses in Tertiles of Reticulated Platelets
Percentage of patients with low responses to aspirin (ASA-LR), clopidogrel
(CLO-LR), and both aspirin and clopidogrel (ASACLO-LR) in tertiles of reticu-
lated platelets. p values were determined using chi-square test among the 3
tertiles.
Figure 3 Proportion of %RPs of Platelets in Lower 20%, Mid-
dle 60%, and Upper 20% Gates of Platelets by Size
RPs  reticulated platelets.P
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August 26, 2008:743–9 Reticulated Platelets and Antiplatelet Therapyertiles of RPs, there were again no differences in platelet
unction on the basis of the dose (Table 2).
ow response to aspirin and clopidogrel. The frequency
f low response to aspirin was significantly higher in the
pper tertile (16 of 30, 53%) compared with the middle (3
f 30, 10%) and lower (5 of 30, 17%) tertiles (p  0.001).
dditionally, the frequency of low response to clopidogrel
as higher in the upper tertile (15 of 30, 50%) compared
ith the other 2 tertiles (20% [6 of 30] and 13% [4 of 30]
n the middle and lower tertiles, respectively, p  0.003).
he number of patients meeting criteria for both aspirin and
lopidogrel low response was also higher in the upper tertile
10 of 30, 33%) compared with the lower (2 of 30, 7%) and
iddle (0%) tertiles (p  0.001) (Fig. 2). Compared with
he lower 2 tertiles, being in the upper tertile conferred a
ensitivity of 83%, specificity of 74%, positive predictive
alue of 33%, and a negative predictive value of 97% (p 
.001) of having a low response to both aspirin and
lopidogrel.
nfluence of platelet size (with flow cytometry) on plate-
et activation. We observed a greater percentage of RPs in
he pool of large platelets (upper 20%) (15.4  16.7%)
ompared with the pool of small platelets (lower 20%) (1.73
.3%, p  0.001) (Fig. 3). Of all RPs, 61% were present in
he large pool compared with 7% of all RPs present in the
mall pool. Greater GP IIb/IIIa expression (5.7  3.1 vs.
.1 1.2, p 0.001) as well as higher P-selectin expression
7.8  4.9 vs. 4.6  2.7, p  0.001) were found in the large
Figure 4 P-Selectin and GP IIb/IIIa
Expression in Small, Large, and All Platelets
P-selectin and glycoprotein (GP) IIb/IIIa expression in small (lower 20%), large
(upper 20%), and all platelets, expressed as mean fluorescence intensity (MFI).
Mean  SEM; p value for t test large versus small platelets.
Platelet Activation Parameters in ASA-LR and A
Table 3 Platelet Activation Parameters in A
Small (Lower 20%)
ASA-NR ASA-LR
P-selectin 4.7 2.7 4.5 2.6
Glycoprotein IIb/IIIa 1.9 1.2 2.4 1.3*
Reticulated platelets 1.4 2.1 2.6 2.8 1*p  0.05 with t test comparing aspirin low responders (ASA-LR) and aspirinompared with the smaller platelets (Fig. 4). Background
ctivation was no different between the large and small
latelets.
When stratified by platelet size and aspirin response,
arge platelets of aspirin low responders had almost twice the
umber of RPs compared with normal responders (23.5 
5.8% vs. 12.5  16.3%, p  0.05). Expression of GP
Ib/IIIa was also elevated in large platelets of aspirin low
esponders compared with normal responders, whereas ex-
ression of P-selectin was no different between the 2 groups
Table 3). Similar platelet activation patterns were seen
hen stratified by responses to clopidogrel (Table 4). These
ata suggest that large platelets demonstrate elevated activ-
ty, particularly in low responders to antiplatelet therapy,
ossibly due to an increased proportion of RPs.
egression analysis. Multiple logistic regression was per-
ormed with age, gender, aspirin dose, MPV, %RPs, and
HF (because it was statistically significant between the
roups), and the only variable that predicted low-response
o both aspirin and clopidogrel was %RPs (p  0.02). With
ultiple linear regression analysis with the same variables,
xpression of GP IIb/IIIa and P-selectin were also signifi-
antly predicted only with %RPs (p  0.03 for both).
ercent RPs also predicted LTA in response to AA (p 
.003) and ADP (p  0.02). Interestingly, age also signif-
cantly predicted LTA response to AA (p  0.001). The
PV and aspirin dose, alone or in addition to %RPs, did
ot predict low response to antiplatelet therapy or platelet
ctivation.
iscussion
e have demonstrated for the first time that platelets from
atients with stable CAD and elevated platelet turnover,
eported by the proportion of circulating RPs, exhibit
ignificantly increased aggregation and activation responses
ven after dual antiplatelet therapy. The number of patients
ith suboptimal or “low response” to aspirin or clopidogrel
r both was clustered among patients with a high proportion
f circulating RPs. We have previously reported an associ-
tion between increased platelet reactivity and the propor-
ion of circulating RPs in healthy volunteers who were
dministered a single dose of 325 mg of aspirin (14). This
tudy confirms our earlier findings in a larger population of
atients and further explores the role of platelet size in
odifying responses to aspirin and clopidogrel. The preva-
ence of aspirin low response in our study (27%) is similar to
R According to Platelet Size
and ASA-NR According to Platelet Size
arge (Upper 20%) All Platelets
NR ASA-LR ASA-NR ASA-LR
5 6.6 4.7 6.4 3.5 5.7 3.5
3.2 6.6 3.2* 3.1 2 4.5 1.8*
16.3 23.5 15.8* 5.6 8.4 10.7 8.1*SA-N
SA-LR
L
ASA-
8.3
5.1
2.5normal responders (ASA-NR).
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s higher than reported rates with AA (31,32), although the
easons for this are unclear. One possibility is that we had an
lder population with known CAD, which in our study
ignificantly predicted responses to AA by regression anal-
sis, consistent with other published studies (33).
Reticulated platelets are recently formed platelets that
eceive their name due to their similarity to red blood cell
eticulocytes and the patterns of distribution of messenger
ibonucleic acid that produces a reticulated pattern after
taining with thiazole orange. The proportion of circulating
Ps is increased in experimental models of enhanced
hrombopoiesis and is increased in patients with diseases
haracterized by increased platelet turnover, such as bleed-
ng and idiopathic thrombocytopenic purpura (11,30,34).
ounger platelets are believed to be more active physiolog-
cally (16,35) and are also increased in acute coronary
yndromes and stroke (12,13). Thus, they are more likely to
articipate in thrombosis. Their role in modulating the
esponses to antiplatelet medications such as aspirin and
lopidogrel are not known. We have described the impact of
oung platelets in modifying these responses, to suggest that
levated platelet turnover or RPs could decrease responses to
ual antiplatelet therapy. It is possible that young platelets
re more reactive (35), and that aspirin and clopidogrel in
he doses currently administered do not adequately suppress
he activity of young platelets. Aspirin’s half-life in the
lasma is short, and once-a-day aspirin might not suffice to
dequately inhibit newly formed platelets in a high turnover
tate. In addition, it is possible that new platelets could
egenerate COX-1 and P2Y12 receptors for activation. They
ight produce enough thromboxane A2 or have enough
eceptors for cross-linking and activation to be physiologi-
ally relevant, as suggested by GP IIb/IIIa expression and
latelet aggregometry in our study. We have previously
emonstrated that elevated RPs are also associated with
ncreased thromboxane synthesis, with inadequate suppres-
ion of COX-1 (14). In addition, non–COX-1–mediated
rocesses, such as through COX-2, have also been sug-
ested to play a role in thromboxane synthesis in young
latelets (14,36,37).
We have also demonstrated an association between plate-
et size and platelet activation after antiplatelet therapy.
hen assessed by flow cytometry, larger platelets had
ignificantly greater activation patterns compared with
maller platelets after antiplatelet therapy. Some studies
Platelet Activation Parameters in CLO-LR and C
Table 4 Platelet Activation Parameters in C
Small (Lower 20%)
CLO-NR CLO-LR
P-selectin 4.3 2.6 5.2 2.8
Glycoprotein IIb/IIIa 1.7 1.2 2.6 1.1*
Reticulated platelets 1.5 2.2 2.3 2.6
*p  0.05 with t test comparing clopidogrel low responders (CLO-LR)ave suggested that increased platelet size independently bodifies platelet function irrespective of age (38). In our
tudy, most of the RPs (60%) were in the large platelet
roup and comprised 15% of all large platelets compared
ith 2% in the small platelet group. In addition, although
ur study is not sufficiently powered to test for differences in
latelet function with respect to MPV, regression analysis
ith platelet size using MPV did not predict responses to
ntiplatelet therapy in addition to %RPs. Thus, platelet size
ould just be a surrogate for young platelets, and we cannot
onclude from this study that large platelets modify re-
ponses to antiplatelet therapy independent of %RPs. This
tudy does provide evidence that large platelets are more
ctive and could potentially have an independent role in
odifying the effects of antiplatelet therapy, although this
ill need to be studied further in later studies.
Aspirin dose did not seem to make any difference in
latelet responses to aspirin. When patients in each tertile of
Ps were stratified into either an 81- or a 325-mg aspirin
ose group, the dose strength did not affect the antiplatelet
ffects of aspirin. Differences between the tertiles persisted
espite the higher aspirin dose, suggesting that an aspirin
ose 81 mg administered once daily would not overcome
he inability of aspirin to adequately inhibit platelets in
atients with a higher platelet turnover (RPs). Whether
spirin or clopidogrel administered in multiple daily doses
rovides more effective platelet inhibition in patients with a
igh platelet turnover remains to be evaluated.
tudy limitations. The main limitation of this study is the
nability to assess clinical outcomes due to the sample size.
arger studies might be required to ascertain clinical rele-
ance and importance. Further mechanistic studies are
ecessary to determine how platelet age and size modify
latelet function after antiplatelet therapy. Absolute platelet
ize of the large and small platelet gate could not be
btained, because the flow cytometer was not equipped to
ccurately provide these measures. Antiplatelet therapy
fficacy with respect to MPV has to be studied in larger
atient populations, because our study was not powered to
tudy this.
onclusions
e demonstrate that an elevated proportion of young
latelets and possibly large platelets are associated with
ncreased platelet reactivity in patients with stable CAD
ho are being treated with dual antiplatelet therapy with
According to Platelet Size
and CLO-NR According to Platelet Size
Large (Upper 20%) All Platelets
-NR CLO-LR CLO-NR CLO-LR
5 7.8 5 5.8 3.5 6.6 3.5
3.2 6.9 2.9* 3 2 4.3 1.8*
16.3 20.7 17.4* 6.3 8.3 9.9 9.7*
pidogrel normal responders (CLO-NR).LO-NR
LO-LR
CLO
7.6
4.9
13.7oth aspirin and clopidogrel. Aspirin dose, when taken once
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